Chief Executive Officer
Jonathan Goldman joins Abzena from his role as an Operating Partner at Welsh Carson where he focused on healthcare investments. He joined WCAS in 2017 following the sale of Aptuit, a former WCAS portfolio company. Jonathan served as the Chief Executive Officer of Aptuit, an integrated small molecule discovery, development and manufacturing CRO from 2013 to 2017, that also operated a sterile fill finish facility. He has 29 years of experience in healthcare. He previously held senior executive positions at ICON Plc, including Global Head of Sales and Point Biomedical, where he served as Chief Medical Officer. Until 2018 he also held appointments as an Associate Clinical Professor of Medicine in the division of Cardiology at the University of California, San Francisco and as an Attending Cardiologist at the San Francisco Veterans Administration Medical Center, following appointments at the John Radcliffe Hospital, Oxford UK as a Consultant Cardiologist.
Jonathan grew up in London where he trained in medicine at St. Bartholomew’s’ Hospital Medical College and in Cardiology at St. George’s Hospital, London. He received BSc, MBBS and MD degrees from the University of London. He also was awarded MBA degrees from Columbia University in New York and the University of California at Berkeley. He serves on the Cardiovascular Research Advisory Board, Oregon Health Sciences University and the Healthcare Pharmaceutical Management advisory board at Columbia University Business School.
Chief Financial Officer
Richard Milbank joined Abzena in 2018 as Chief Financial Officer. Richard has deep experience in the pharma services sector including 8 years as CFO of NextPharma which he helped grow into a large Global CDMO.
Richard has also served in senior financial roles in several leading companies in the Medical and Food industries.
He is a Chartered Accountant with broad transaction experience gained over 9 years at PwC and Arthur Andersen. Richard has a BSc in Economics at Hull.
Chief Commercial Officer
As CCO Philip Payne leads global business development with a particular focus on growing the company’s business in the European and UK regions. Mr. Payne joins Abzena following senior commercial roles at global Pharmaceutical Services companies including Concept Life Sciences, Aptuit, and Catalent Pharma Solutions. He is broadly experienced in integrated solutions for contract services that span the areas of discovery, development and manufacturing. Mr. Payne received a Bachelor Degree in Chemistry and Environmental Science from the University of Kent in the UK.
Chief Business Officer
Before joining Abzena, Sven was Director, Global Sales and Business Development for the Cell Therapy Technologies business unit of Terumo BCT. He was successful in growing business and new collaborations within cell therapy and immunotherapy.
Prior to Terumo BCT, Sven was Vice President, Global Business Development at Catalent Biologics, responsible for the team's pre-clinical through Phase I/II GMP manufacturing business. He also launched the SMART Tag® antibody drug conjugation platform. Before Catalent, Sven spent five years as Director, Business Development, with Crucell (Johnson & Johnson) and ten years with Biogen.
Sven started his career, after graduating with a BA in biology from Lake Forest College.
Chief Scientific Officer
Campbell has over 19 years’ experience working in the biotech and diagnostics sectors, occupying senior management positions with Piramed Pharma (Director, Development Programmes), Immune Targeting Systems (R & D Director) and Oxford Immunotec (General Manager, Immunology Products). He has extensive experience in developing novel biologics and vaccines for cancer, inflammatory and infectious diseases, leading them through development and regulatory processes including pre-clinical evaluation and translation in the clinic.
Campbell has a PhD in Immunology from the University of Manchester and has published a number of papers in T cell biology, immunomodulators and vaccines.
Senior Vice President of Chemistry and Site Head
Sanjeevani joined The Chemistry Research Solution LLC (acquired by Abzena in 2015) in early 2010 as Principal Scientist and was successively promoted to Director of Chemistry and in 2016 to Vice President of Chemistry and Site Head. She has worked on a host of projects involving toxic payloads and antibody-drug conjugates along with other multi-step organic syntheses and has gained extensive experience in solving complex organic chemistry problems.
Sanjeevani has more than 20 years’ experience working in chemical, pharmaceutical, and biotech companies as well as academic institutes. She has held R&D executive positions at Imperial Chemical International and Bombay Drug House. During her academic career, Sanjeevani was a Professor in Pharmaceutical Chemistry at academic institutions where she mentored MS and PhD students as research advisor.
Sanjeevani has a PhD in Medicinal Chemistry from the Institute of Chemical Technology, University of Mumbai. She has published a number of research/review articles on multi-step organic synthesis of novel molecules, lead optimization, payload-linker chemistry and computer-aided drug design (CADD) for a variety of therapeutic areas and also co-authored a book on the synthon approach to the synthesis of drugs.
Chief Operating Officer
Ms. Hall focuses on the growth of Abzena as the leading Partner Research Organization (PRO) for outsourced integrated gene to GMP services. Prior to Abzena Kimball served for 4 years at Genetech as SVP and Global Head of Drug Substance, as well as a member of the Genentech Executive Committee, with responsibility for 7 internal sites and 4,300 people covering both biologics and small molecules. Ms. Hall was also responsible for 27 external manufacturing locations. Her accomplishments included ensuring a strong Quality and Safety Culture, supporting 5 new commercial product launches, and establishing small volume production. Before joining Genentech, Ms. Hall served for 16 years at Amgen in multiple roles of increasing responsibility, culminating as VP of Manufacturing.
Ms. Hall holds a BS in Microbiology from the University of Washington. She has held a variety of Board and Advisory Board positions, including being a member of the Genentech Executive Committee, Genentech’s Patient Access Board, and as an advisor to Genentech’s Global Women’s Professional organization.
Senior Vice President Process and Operations
Bo Adair is Senior Vice President Process and Operations, based in San Diego and leads project management and process improvement globally. He is a twenty-five-year veteran of the industry, having served in senior roles at contract research organisations including Aptuit, and Harlan Laboratories as well as leading management consulting organisations. He has consulted extensively with complex organisations including Bayer, Eli Lilly, Johnson & Johnson, Cardinal Healthcare, and the United States Army. He began his career as a United States Marine. His background includes an MBA from the Wirtschaftsuniversität Wien & University of South Carolina, an undergraduate degree from Auburn University, and a qualification as a Lean Six Sigma Master Black Belt.
Bo focuses on excellence of integrated project delivery within and across Abzena’s sites, leveraging project management, process improvement and enabling technologies. He ensures all processes are optimised to ensure the highest quality standards.
Global Head of Quality
Ms. Sapinoso is responsible for the oversight of Quality Assurance, Quality Control, and Analytical Development departments. She is also responsible for regulatory compliance across the Abzena sites.
Prior to joining Abzena, Ms. Sapinoso served in senior roles at global contract manufacturing organizations. She was formerly Vice President of Quality and Regulatory at Aji Bio-Pharma (Ajinomoto Althea), where she was responsible for the Quality in Drug Substance, Drug Product and testing operations from early clinical through commercial phase.
Ms. Sapinoso brings over 22 years of Quality and Regulatory experience within the pharmaceutical and biotechnology industries, supporting both large and small molecule drug manufacturing. She has assisted in bringing 11 drug products candidates to commercial approval in 11 countries, with a track record of no critical inspectional findings during pre-approval site inspections.